Kornimate/medical-research-clean huggingface dataset:
healing after connective tissue graft harvesting in the palatal area with and without suture

Conditions: Wound Healing

Summary: this study evaluated the outcomes in the early healing of palatal wounds after harvesting a subepithelial connective tissue graft (sctg) using the single incision technique with placement of a collagen haemostatic sponge (chs) without suturing the palate. the primary outcome of this study was to evaluate the early wound healing index (ehi).

the aim of this study was to compare the outcomes in the early wound healing after harvesting a subepithelial connective tissue graft (sctg) using the single incision technique and collagen haemostatic sponge (chs) placement, with and without suturing the palate. 36 subjects were randomized to receive (n=18, suture group-sg) or not a suture (n=18, no suture group-nsg). outcomes variables were: early healing index (ehi) at 7, 14 and 30 days, self-reported pain using a visual analogue scale (vas) at 7 and 14 days, immediate (ib) and delayed bleeding (db). data obtained were compared by fisher's exact test, t test for independent sample, mann-whitney test (u test) and wilcoxon sign test as appropriate. the level of significance was set at p \< 0.05. statistical analysis was performed with infostat version 2015.

Eligibility criteria:
inclusion criteria * subjects with an indication of mucogingival surgery for single gingival recession treatment that required harvesting a subepithelial connective tissue graft * age \>18 years ≤ 60 years. * periodontally and systemically healthy. * palatal fibromucosa width ≥ 2mm evaluated with a north carolina probe placed perpendicular to the hard palate, prior to surgery. exclusion criteria * smoking. * contraindications for periodontal surgery. * subjects presenting coagulation disorders (history of haemophilia, von willebrand disease or anticoagulant therapy). * subjects taking medications known to interfere with periodontal tissue health or healing. * subjects that had been operated on the palate (connective tissue removed) previously from that same donor area.

Keywords: wound healing palate connective tissue harvesting single incision
evaluation of breastmilk microbiota as a function for immunity

Conditions: Vaginal Infection; Breastmilk Collection

Summary: the aim of this study is to evaluate the difference of breast milk microbiota between mothers with and without vaginal infections during pregnancy.

the maternal microbiota is one of the relevant factors in the development of the infant's immune system, whereby the colonization of microbes in human begins at birth, when the newborn baby is exposed to maternal vaginal, gastrointestinal microbiota and as well as the microbes from the external environment. the neonatal intestine is colonized by symbiotic bacteria can be divided into four main steps; (i) acquisition of maternal vaginal, colonic, and skin flora at birth; (ii) introduction of oral feedings (breastfeeding or formula feeding); (iii) weaning; and (iv) acquisition of complete adult colonization. breastfeeding is associated with the protection of the infants from either infections or infection-related conditions, such as gastroenteritis, upper and lower respiratory tract infection, acute otitis media, urinary tract infection, neonatal septicaemia and necrotizing enterocoltis. the protection is through the combination of action of the breast milk components, such as maternal immunoglobulins, immunocompetent cells, or variety of anti-microbial compounds. besides that, breast milk also contains prebiotic substances which may selectively stimulate the growth of limited number of beneficial bacteria in the gut. a total number of 100 lactating mothers are needed for this study. subjects will be recruited from husm kubang kerian, usm main campus penang, and institut perubatan \& pergigian termaju usm penang. the subjects will be explained on all related information in the consent form prior to signing. the procedure of collecting sample is hands must be washed before milk expression, and nipples are cleaned with sterile water and alcohol swab. 15ml of fresh breast milk will be collected into a tube and stored at -20℃ until further analyses.

Eligibility criteria:
inclusion criteria: * lactating women * willing to commit throughout the experiment exclusion criteria: * long term medication due to certain illnesses for over 3 months during pregnancy * gestational diabetes during pregnancy * history of diabetes, coronary heart disease, and hypertension in life * bmi before pregnancy above 24.9 * consuming probiotic product during pregnancy * consuming probiotic product during lactation period

Keywords: breastmilk vaginal infection immunity properties
a study of disease progression in participants with geographic atrophy secondary to age-related macular degeneration

Conditions: Geographic Atrophy

Summary: this study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (ga) due to age-related macular degeneration (amd). the study is also intended to generate new information on the relationship between genetics and ga progression. this is a global, prospective, multicenter, epidemiologic study enrolling participants with ga secondary to amd. the study visits are scheduled to occur every 6 months. the anticipated duration of the study is up to 48 months. there is a planned interim analysis around the 2-year time window for the study.


Eligibility criteria:
inclusion criteria: * for women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year for at least 30 days after the last fluorescein dye administration * the study is being conducted in participants with ga in both study eye and non-study eye (bilateral ga) with no evidence of prior or active choroidal neovascularization (cnv) exclusion criteria: * previous participation in any studies of investigational drugs for ga or dry amd (except for studies of vitamins and minerals) * ga in either eye due to causes other than amd * history of vitrectomy surgery, submacular surgery, or any surgical intervention for amd * previous laser photocoagulation for cnv, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy * any ocular or systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments * requirement for continuous use of therapy indicated in prohibited therapy in the study protocol
a trial of clobetasol propionate versus hydrocortisone in children with alopecia areata

Conditions: Alopecia Areata

Summary: the use of topical steroids in the treatment of alopecia areata in children is common practice. however, no particular potency of steroid is accepted as the standard treatment due to the paucity of high quality evidence in the dermatology literature to substantiate their use. two randomized controlled trials exist assessing topical steroid efficacy in this disorder, both have methodological limitations. the question remains as to which topical steroid is safe and efficacious for use. we performed a double blinded controlled trial to assess the usefulness of a class 1 topical steroid (clobestasol proprionate 0.05%) compared with a class 7 topical steroid (hydrocortisone 1%) in children with alopecia areata.


Eligibility criteria:
inclusion criteria: * age 2 to 16 years * new patients presenting to the hospital for sick children * clinical confirmation of alopecia areata * hair loss between 10 -75% exclusion criteria: * skin or medical problems requiring use of oral steroids * immunosuppressants or puva for 4 weeks prior to the study * use of inhaled and or intranasal steroids for 14 days prior to trial * topical medicaments for 7 days prior to the trial

Keywords: alopecia areata hydrocortisone clobetasol propionate randomized controlled trial
a study to evaluate the effectiveness and safety of eus-guided transluminal drainage with 'niti-s spaxus stent'

Conditions: Pancreatic Pseudocyst

Summary: the purpose of this study is to evaluate the safety and effectiveness of endoscopic ultrasound (eus)-guided transluminal drainage with 'niti-s spaxus stent' for the treatment of pancreatic pseudocyst.

'niti-s spaxus stent' is a newly designed lumen-apposing fully covered self-expandable metal stent. it is indicated for use in patients with pancreatic pseudocyst. consecutive subject data should be collected at discharge, stent removal (day 30 or 60), and day 20 post niti-s spaxus stent removal.

Eligibility criteria:
inclusion criteria: * pancreatic pseudocyst ≥6cm in size, with ≥70% fluid content that is eligible for transluminal drainage * patient willing to provide written informed consent and comply with follow-up requirements exclusion criteria: * ineligible for endoscopic intervention * pancreatic pseudocyst with severe internal septation * platelet count \ 1.5 * hemodynamic instability (e.g. shock) * active infectious disease (e.g. endocarditis, meningitis) * participating in any other investigational drug or device clinical trial within past 3 months * female of child-bearing potential who are unable to take adequate contraceptive precautions, are known to be pregnant, or are currently breastfeeding an infant

Keywords: endoscopic ultrasound guided transluminal drainage
exploring the effect of an intervention on women's physical activity behaviour

Conditions: Physical Activity

Summary: physical activity has been shown to reduce the risk of chronic diseases and promote physical and mental health and wellbeing, yet few women are active enough to see these benefits. wearable activity trackers show promise for helping people increase their physical activity levels by supporting self-monitoring. however, few researchers have examined how providing people with these devices impacts physical activity levels, or motivation for physical activity which is a significant and robust predictor of physical activity. based on previous research, it is possible that women's physical activity levels would be more likely to increase if they received an autonomy-supportive intervention to enhance motivation in addition to a wearable activity tracker. a pilot, three-armed randomized controlled trial was developed to test this hypothesis and to assess if changes in perceived autonomy-support, basic psychological need satisfaction/thwarting, motivational regulations, wellbeing indicators are associated with changes in physical activity over time.


Eligibility criteria:
all participants will need to meet the following inclusion criteria to participate in the intervention: 1. are a woman between the ages of 18 and 65 years 2. can understand, read, and speak in english 3. are able to safely engage in physical activity 4. are not currently pregnant or lactating 5. currently participating in less than 150 minutes of moderate or vigorous intensity physical activity and less than two strength training sessions per week 6. are overweight or obese (i.e., have a body mass index greater than 25kg/m2) 7. have access to the internet and an email account 8. have not used a wearable activity tracker within the past year (e.g., fitbit, apple watch, garmin, polar) 9. live within 50km of the university of ottawa

Keywords: physical activity obesity pilot study randomized controlled trial women ehealth
a study with jaktinib hydrochloride cream applied topically to subjects with alopecia areata

Conditions: Alopecia Areata(AA)

Summary: this study includes a dose escalation part(phase i) and a dose extension part(phase ii).

in phase i of this study, a multi-center, randomized, placebo parallel control design was adopted. enrolled subjects were randomly assigned to the experimental group or the placebo group.a total of 40 subjects are expected to be enrolled in about 4 centers. in phase ii of this study, a multi-center, randomized, double-blind parallel, placebo-controlled design was adopted. enrolled subjects were randomly assigned to the experimental group or the placebo group.about 120 subjects are expected to be enrolled in about 10 centers.

Eligibility criteria:
inclusion criteria: * 18 \~ 65 years old (including boundary value), regardless of gender; * diagnosis of alopecia areata; * hair loss accounts for 5% \~ 49% of the total scalp area; * the duration of hair loss is at least 6 months, the longest is not more than 5 years; * patients can complete treatment for at least 6 months; * about fertility needs meet the following criteria: the results of serum pregnancy tests performed by fertile women during screening visits must be negative, and the results of human chorionic gonadotropin tests performed before the initiation of the study drug must be negative;women who were fertile and men who had not received vasectomies were required to use effective contraception throughout the study period beginning with the informed consent and up to six months after the last administration; * subjects will voluntarily participate in the study after learning about the content and potential adverse drug reactions and must sign an irc-approved informed consent prior to beginning any examination required by the study; * subject is willing and able to comply with scheduled visits, treatment plan, study drug administration, and other study procedures. exclusion criteria: * the following causes of hair loss should be excluded: hair loss caused by androgenic alopecia,syphilis, thyroid diseases, etc. * acute diffuse and total alopecia of the female scalp; * prior history of serious chronic diseases, such as thyroid disease, liver disease, malnutrition, heart disease, nervous system disease, gastrointestinal dysfunction, tumor and mental illness, etc; * human immunodeficiency virus infection, hepatitis c virus infection, hepatitis b virus infection; * participated in a trial for a topical or oral jak inhibitor; * allergic reactions to active ingredients or excipients are known or determined by the investigator; * receipt of treatment known to potentially affect the course of aa within last 3 month; * in the opinion of the investigator , the subject is inappropriate for entry into this study.
the influence of sedation and general anesthesia to patients' psycho-emotional state undergoing wisdom teeth extraction

Conditions: Teeth, Impacted; Tooth-loss; Anxiety; Fear

Summary: the aim of the study is to evaluate, wheather the sedation or general anesthesia in third molar extractions influence the patient's psycho-emotional status. it is believed that the type of anesthesia may influence not only the psycho-emotional status after the procedure, but also before the procedure.

a prospective pilot study was conducted on adult patients who were admitted to the faculty of surgery at lsmu kk hospital for removal of all four wisdom teeth with sedation or general anesthesia. the patients were given one day to complete the given questionnaires. they were asked to complete three questionnaires: a) before the surgery, i.e. at the time the patient was hospitalized; b) the same day prior to surgery; c) ten days after the surgery. the operating doctor also filled out a questionnaire ten days after the surgery. the aim of the study is to evaluate, wheather the sedation or general anesthesia in third molar extractions influence the patient's psycho-emotional status. it is believed that the type of anesthesia may influence not only the psycho-emotional status after the procedure, but also before the procedure.

Eligibility criteria:
inclusion criteria: * patient age ≥ 18 years; * indicated removal of all 4 wisdom teeth; * non-use of nsaids, anticoagulants; * no acute inflammation in the operated area; * no history of common conditions that contraindicate oral surgery. for example, uncontrolled diabetes, cardiovascular disease; * patients agreed to participate in the study. exclusion criteria: * pregnant, breastfeeding women; * individuals, formerly treated with radiation; * patients who participated in studies related to the assessment of psycho-emotional status; * patients with obvious mental, intellectual or physical disabilities limiting the participation in the study.
inter-hospital transfer to a vascular neurology unit after telethrombolysis

Conditions: Ischemic Stroke

Summary: early thrombolysis is essential in treating ischemic strokes. the time window for thrombolysis is limited to 4,5 hours after symptoms onset. in the french region of franche comté, in order to reduce the thrombolytic delay, a telemedicine network was developed between the neurovascular reference unit (nvu) localised in the university hospital of besançon and the peripheral hospital centres. patients may then be transported to the nvu immediately after the thrombolysis initiation. the aim of our study was to assess the relevance of a systematic medicalization of transfer to the nvu of patients with stroke who were telethrombolyzed before. it was a retrospective, monocentric and observational study conducted over 24 months, in franche-comte (france).

stroke is a major health problem with increasing incidence. it represents the leading cause of disability and the third cause of death in france. there are two main types of stroke: ischemic (80%) or hemorrhagic (20%). early thrombolysis is essential in treating ischemic strokes. the time window for thrombolysis is limited to 4,5 hours after symptoms onset. in the french region of franche comté, in order to reduce the thrombolytic delay, a telemedicine network was developed between the neurovascular reference unit (nvu) localised in the university hospital of besançon and the peripheral hospital centres. patients may then be transported to the nvu immediately after the thrombolysis initiation. the aim of our study was to assess the relevance of a systematic medicalization of transfer to the nvu of patients with stroke who were telethrombolyzed before. it was a retrospective, monocentric and observational study conducted over 24 months, in franche-comte (france). evaluation of neurological status was made with the glasgow score (gcs) and national institute of health stroke score (nihss). the respiratory (spo2; needs o2) and hemodynamic status (arterial blood pressure, heart rate) were assessed as well as the need for medical resuscitation at different times of the transport (thrombolysis, transfer, arrival at the regional university hospital centre).

Eligibility criteria:
inclusion criteria: * patient with ischaemic stroke * emergency department admission between 01/01/2012 and 12/31/2013 * telemedicine stroke consult * thrombolysis therapy * patient transfered to nvu after thrombolysis initiation * transfer staffed by a qualified physician exclusion criteria: * transfer non staffed by a qualified physician

Keywords: telemedecine thrombolysis
the treatment of depression with botulinum type a toxin

Conditions: Depression

Summary: a 24-week randomized, double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with botox injections. subjects participating will have their photos taken and complete a questionnaire regarding their depression. they will see a psychiatrist at every visit who will assess their depression.

participants will be assigned to receive either placebo or botulinum toxin injections in the forehead

Eligibility criteria:
inclusion criteria: 1. male/female between the ages of 18 and 65 2. major depression disorder as defined by dsm iv criteria and diagnosed by a psychiatrist. dsm (diagnostic and statistical manual) iv criteria for depression are: a depressed mood or anhedonia for at least a two week period. this mood must represent a change from the person's normal mood; social, occupational, educational or other important functioning must also be negatively impaired by the change in mood. major depressive disorder cannot be diagnosed if a person has a history of bipolar disorder or if the depressed mood is better accounted for by substance abuse or a psychotic disorder. in addition, the patient must have 5 of the following symptoms: * significant weight loss or weight gain. * insomnia or hypersomnia * psychomotor agitation or retardation * feelings of worthlessness or excessive guilt * poor concentration * fatigue or loss of energy * suicidal thoughts 3. history of depression for at least 6 months 4. initial score 14 or higher on initial hamilton depression rating scale. 5. melancholic facial expressions amenable to treatment with botox. photos will be taken of potential participants and ranked independently by two investigators, on a scale of 1-10 based on how negative they look, 10 being the highest. patients with an average score of 6 or above will be included in the study exclusion criteria: 1. active substance abuse 2. bipolar depression 3. subjects who are pregnant, nursing or trying to become pregnant during study participation 4. subjects who are currently on more than 3 psychiatric medications at the time of enrollment 5. current medications used to treat depression must be stable for at least 60 days prior to enrollment 6. previous botox treatment 7. the principle investigator has determined that this study is not in the best interest of the subject and therefore the subject will not be enrolled.

Keywords: botox depression
clinical study to evaluate effectiveness of digital refraction

Conditions: Myopia; Astigmatism

Summary: prospective, comparative, randomized, non-masked clinical study to compare the a digital refraction with logmar va testing utilizing trial lenses, to standard manual refraction using a phoropter, and logmar va testing, in accuracy of visual acuity measurement.

a digital refraction tool is a device meant to measure visual acuity and to subjectively measure refractive value for a patient's eye for the conditions of myopia and astigmatism. it is intended for adults aged 22 to 55 years that have no prior correction with up to 3.00 diopters (d) of myopia and up to 2.00 d of astigmatism, or those with prior correction up to 10.00 d of myopia and require an over-refraction of no more than 2.75 d. logmar (etdrs) chart to measure visual acuity. the manual manifest refraction is performed by an eyecare specialist using a phoropter. the logmar visual acuity chart is used to measure visual acuity. the manual refraction will be used in this study for obtaining the refractive error of each eye.

Eligibility criteria:
inclusion criteria: 1. subject must be between 22 and 55 years of age at the time of consent. 2. subject must have a refractive error 1. with no greater than -3.00 d myopia and -2.00 d astigmatism in either eye. 2. with prior correction of no greater than -10.00 d myopia and requiring over-refraction of no more than 2.75 d in either eye. 5. subjects with best corrected visual acuity (bcva) of 20/32 or better. exclusion criteria: 1. subjects with diabetes mellitus. 2. subjects using ophthalmic or systemic corticosteroids. 3. subjects with autoimmune conditions. 4. subjects with active corneal or conjunctival infection. 5. subjects with active corneal, conjunctival, or intraocular inflammation (ie, uveitis). 6. subjects with diabetic retinopathy. 7. subjects with glaucoma or ocular hypertension. 8. subjects with macular degeneration. 9. subjects with previous ocular surgery. 10. subjects on antihyperglycemic agents; corticosteroids; hydroxychloroquine (plaquenil) and chloroquine (aralen); tamoxifen (nolvadex). 11. pregnancy 12. subjects who, in the judgment of the investigator, may be inappropriate for the intended study procedures.